Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States

Philip E. Castle, Diane Solomon, Debbie Saslow, Mark Schiffman

Research output: Contribution to journalReview article

16 Scopus citations


The development of a prophylactic human papillomavirus (HPV) vaccine that potentially may eliminate a majority of cervical cancers is a landmark in cancer prevention. Cervical screening, however, will continue to play an important role for the foreseeable future. Maintaining screening at the same intensity and simply adding on the expense of vaccination would result in redundancy of prevention efforts at enormously increased costs without necessarily further reducing cervical cancer mortality. Effectively integrating vaccination and screening efforts will be a critical and evolving challenge over the next decade; this will require understanding not only the impact of vaccination on reducing cervical abnormalities but also the influence of vaccination on screening test performance.

Original languageEnglish (US)
Pages (from-to)3031-3035
Number of pages5
Issue number10 SUPPL.
StatePublished - Nov 15 2008
Externally publishedYes



  • Cervical abnormalities
  • Colposcopy-guided biopsy
  • Oncogenic human papillomavirus testing
  • Positive predictive value
  • Prevention
  • Screening
  • Viral-like particle vaccines

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this